You are here

gefapixant

FDA panel flags insufficient data for Merck's chronic cough drug

FDA panel flags insufficient data for Merck's chronic cough drug

Reuters

Flag link:

FDA skeptical of Merck’s gefapixant, even after cough recount

FDA skeptical of Merck’s gefapixant, even after cough recount

Fierce Biotech

Flag link:

Merck plans to count coughs and months until gefapixant is back in FDA hands

Merck plans to count coughs and months until gefapixant is back in FDA hands

Fierce Biotech

Flag link:

Merck: FDA Rejects Gefapixant Application, Requests More Data

Merck: FDA Rejects Gefapixant Application, Requests More Data

Marketwatch

Flag link:

Bellus soars on positive mid-stage readout for its Merck cough rival, despite a failure in atopic dermatitis

Bellus soars on positive mid-stage readout for its Merck cough rival, despite a failure in atopic dermatitis

Endpoints

Flag link:

FDA says it needs a little more time to decide on Merck's P2X3 for chronic cough

FDA says it needs a little more time to decide on Merck's P2X3 for chronic cough

Endpoints

Flag link:

Chasing Merck & Co, Bayer builds case for cough drug eliapixant

Chasing Merck & Co, Bayer builds case for cough drug eliapixant

Pharmaforum

clinical trials

Flag link:

FDA accepts gefapixant for review in cough, positioning Merck to get head start on Bayer and Bellus

FDA accepts gefapixant for review in cough, positioning Merck to get head start on Bayer and Bellus

Fierce Biotech

Flag link:

Merck's gefapixant successful in late-stage chronic cough studies

Merck's gefapixant successful in late-stage chronic cough studies

Seeking Alpha

clinical trials

Flag link:

Merck hits goal in cough phase 3 but yet to quash tolerability concern

Merck hits goal in cough phase 3 but yet to quash tolerability concern

Fierce Biotech

clinical trials

Flag link: